WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 4 fonti

New Drug Approved for Thyroid Eye Disease

Veligrotug labeling shows data for both the active and chronic forms of TED

Raccontata damorningstar.comhealio.commedpagetoday.combenzinga.com

Confronto fonti

4 prospettive sulla stessa storia
AI · summaries
medpagetoday.comStai leggendo2 g fa

New Drug Approved for Thyroid Eye Disease

Veligrotug labeling shows data for both the active and chronic forms of TED

originale
morningstar.com5 g fa

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment…

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Leggi questa versione → originale
healio.com3 g fa

FDA approves Lumvoa for thyroid eye disease

The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics. The approval was supported by data…

Leggi questa versione → originale
benzinga.com2 g fa

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.

Leggi questa versione → originale

Timeline cronologica

  1. sabato 27 giugno 2026·morningstar.com

    Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

    Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

  2. lunedì 29 giugno 2026·healio.com

    FDA approves Lumvoa for thyroid eye disease

    The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian…

  3. lunedì 29 giugno 2026·medpagetoday.com

    New Drug Approved for Thyroid Eye Disease

    Veligrotug labeling shows data for both the active and chronic forms of TED

  4. lunedì 29 giugno 2026·benzinga.com

    Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid

    FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.